Avalo Therapeutics (AVTX) Other Non Operating Income (2020 - 2025)
Avalo Therapeutics posted quarterly Other Non Operating Income of -$3000.0 for Q3 2025, up 40.0% year-on-year from -$2142.9 in Q3 2024, and up 40.0% on a QoQ basis from -$5000.0 in Q2 2025.
Avalo Therapeutics (AVTX) has 6 years of Other Non Operating Income data on file, last reported at -$3000.0 in Q3 2025.
- For the quarter ending Q3 2025, Other Non Operating Income rose 40.0% year-over-year to -$3000.0; the trailing twelve-month figure through Sep 2025 stood at -$13000.0 (up 72.34% YoY), and the FY2024 full-year result was -$5000.0, up 88.1% from the prior year.
- Other Non Operating Income for Q3 2025 stood at -$3000.0, up from -$5000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $78000.0 in Q4 2023 and bottomed at -$180000.0 in Q1 2023.
- The 5-year median for Other Non Operating Income is -$5000.0 (2021), against an average of -$24727.3.
- Peak annual rise in Other Non Operating Income reached 290.0% in 2023, while the deepest fall reached 800.0% in 2023.
- A 5-year view of Other Non Operating Income shows it stood at -$15000.0 in 2021, then jumped by 233.33% to $20000.0 in 2022, then surged by 290.0% to $78000.0 in 2023, then plunged by 106.41% to -$5000.0 in 2024, then surged by 40.0% to -$3000.0 in 2025.
- The last three Other Non Operating Income figures came in at -$3000.0 (Q3 2025), -$5000.0 (Q2 2025), and -$5000.0 (Q3 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -3,000.00 |
| Jun 30, 2025 | -5,000.00 |
| Sep 30, 2024 | -5,000.00 |
| Mar 31, 2024 | -120,000.00 |
| Dec 31, 2023 | 78,000.00 |
| Sep 30, 2023 | -17,000.00 |
| Mar 31, 2023 | -180,000.00 |
| Dec 31, 2022 | 20,000.00 |
| Mar 31, 2022 | -20,000.00 |
| Sep 30, 2021 | -15,000.00 |
| Jun 30, 2021 | -5,000.00 |
| Dec 31, 2020 | -38,000.00 |
| Sep 30, 2020 | 19,000.00 |
| Jun 30, 2020 | 398,000.00 |
| Mar 31, 2020 | 11,000.00 |